June 7, 2021
The FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway.
May 13, 2021
Today, I adopted CDC’s Advisory Committee on Immunization Practices’ (ACIP) recommendation that endorsed the safety and effectiveness of the Pfizer-BioNTech COVID-19 vaccine and its use in 12- through 15-year-old adolescents. CDC now recommends that this vaccine be used among this population, and providers may begin vaccinating them right away.
April 23, 2021
Following a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Janssen (Johnson & Johnson) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.
April 14, 2021
The CDC and the FDA are reviewing data involving six U.S. cases of a rare type of blood clot in individuals after receiving the Johnson & Johnson (J&J) COVID-19 vaccine that were reported to the Vaccine Adverse Events Reporting System (VAERS).
April 8, 2021
A lawsuit has been filed against Roper St. Francis alleging a breach of private patient data, including financial and medical information, was compromised.
April 2, 2021
The Centers for Disease Control and Prevention (CDC) updated its travel guidance for fully vaccinated people to reflect the latest evidence and science.
March 19, 2021
A bill headed through the S.C. Statehouse would require doctors to offer lifesaving overdose reversal drugs to some patients who might potentially need them, even as the largest physicians’ lobbying group in the state expresses concern the law would be an overreach.
March 16, 2021
Vaccination of about 88% of Americans who received the first dose of Pfizer/BioNTech or Moderna’s COVID-19 vaccines was complete, a study of over 12 million people by the U.S. Centers for Disease Control and Prevention (CDC) showed.
March 1, 2021
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).